The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results from phase 2 registration trial of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Lead-in completed, expansion stage ongoing.
 
Naveen Pemmaraju
Honoraria - Incyte; LFB Biotechnologies; Novartis
Consulting or Advisory Role - Incyte; LFB Biotechnologies; Novartis
Research Funding - Incyte; Novartis; Stemline Therapeutics
 
Andrew A. Lane
Consulting or Advisory Role - N-of-One
Research Funding - Stemline Therapeutics
 
Kendra Lynn Sweet
Honoraria - ARIAD; Novartis; Pfizer
Consulting or Advisory Role - ARIAD; Novartis
Speakers' Bureau - ARIAD; Novartis; Pfizer
Research Funding - Incyte; Karyopharm Therapeutics
 
Anthony Selwyn Stein
Honoraria - Amgen; Stemline Therapeutics
Consulting or Advisory Role - Amgen
Speakers' Bureau - Amgen
Research Funding - Amgen; Pharmacyclics; Seagen; Stemline Therapeutics
Travel, Accommodations, Expenses - Amgen
 
Sumithira Vasu
No Relationships to Disclose
 
William G. Blum
Consulting or Advisory Role - Boehringer Ingelheim; Celator; Genentech
Research Funding - Abbvie; Boehringer Ingelheim
Travel, Accommodations, Expenses - Celator; Celgene
 
David Rizzieri
Consulting or Advisory Role - Gilead Sciences; incyte; Millennium (I); novartis; onyx (I); pfizer; pharmacyclics; Sanofi; Seagen
Speakers' Bureau - Celgene; Celgene (I); Gilead Sciences; incyte; Millennium (I); Seagen
 
Eunice S. Wang
Consulting or Advisory Role - Daiichi Sankyo; Sigma-Tau; Spectrum Pharmaceuticals
Speakers' Bureau - Incyte
Research Funding - Immunogen (Inst)
 
Madeleine Duvic
No Relationships to Disclose
 
Janice Chen
Employment - Stemline Therapeutics
Stock and Other Ownership Interests - Stemline Therapeutics
Travel, Accommodations, Expenses - Stemline Therapeutics
 
Shay Shemesh
Employment - Stemline Therapeutics
Stock and Other Ownership Interests - Stemline Therapeutics
Travel, Accommodations, Expenses - Stemline Therapeutics
 
Peter McDonald
Employment - Stemline Therapeutics
Stock and Other Ownership Interests - Stemline Therapeutics
Travel, Accommodations, Expenses - Stemline Therapeutics
 
Christopher Brooks
Employment - Stemline Therapeutics
Stock and Other Ownership Interests - Stemline Therapeutics
Patents, Royalties, Other Intellectual Property - Stemline Therapeutics
Travel, Accommodations, Expenses - Stemline Therapeutics
 
Hagop M. Kantarjian
Research Funding - Amgen (Inst); ARIAD (Inst); Bristol-Myers Squibb (Inst); Delta-Fly Pharma (Inst); Novartis (Inst); Pfizer (Inst)
 
Marina Konopleva
Stock and Other Ownership Interests - Reata Pharmaceuticals
Honoraria - Abbvie; Calithera Biosciences; Genentech
Consulting or Advisory Role - AbbVie
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Cellectis (Inst); Genentech (Inst); Lilly (Inst); Novartis (Inst); Stemline Therapeutics (Inst)